<DOC>
	<DOC>NCT02520635</DOC>
	<brief_summary>The primary purpose of the study is to evaluate the efficacy and safety of supra-early post-surgery chemotherapy versus standard TEMODALÂ® regimen in treatment of patients with newly diagnosed glioblastoma multiforme. The secondary purpose is to assess the efficacy of supra-early post-surgery chemotherapy in release brain edema.</brief_summary>
	<brief_title>Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1. Patients with prior histological confirmation of newly diagnosed primary glioblastoma multiforme in supratentorial cerebral hemisphere. 2. Gross total resection or partial resection (imaging) &gt;70%. 3. Chemoradiotherapy to be expected from Week 5 (Day 29) after surgery. 4. Age &gt;=18 and &lt;=70 years. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. 6. Life expectancy &gt;=9 months. 7. Laboratory test values must satisfy the following criteria: 1. absolute neutrophil count &gt;=1.5 x 10^9/L; 2. platelet count &gt;=100 x 10^9/L; 3. hemoglobin &gt;=80 g/L; 4. blood urea nitrogen and creatinine &lt; 1.5 x upper limit of normal value (ULN); 5. total bilirubin and direct bilirubin &lt; 1.5 x ULN; 6. alanine aminotransferase and aspartate aminotransferase &lt; 3 x ULN; 7. alkaline phosphatase &lt; 2 x ULN. 8. Patients must be willing to provide written informed consent. 9. Patients of childbearing potential (including female subjects and the female partners of male subjects) must use an effective method of contraception. 1. Patients without prior histological confirmation of primary glioblastoma multiforme. 2. Patient with previous or current malignancies at other sites. 3. Patient who received chemotherapy, radiotherapy for study indication, or other medications for antitumor indication prior to surgery. 4. Patient with recurrent or multiple malignant glioma (including gliomatosis cerebri). 5. Patient with metastatic lesions at the subtentorial or outside of calvaria. 6. Patient who received chemotherapy or radiotherapy sensitizers for head or neck tumor. 7. Patient who received radiotherapy at head or neck which leads to radiotherapy domain overlapping. 8. Frequent vomiting or medical condition that could interfere with oral medication intake (eg, partial bowel obstruction). 9. Known human immunodeficiency virus (HIV)positive or acquired immune deficiency syndrome (AIDS)related illness. 10. Woman who is pregnant or breastfeeding. 11. Patient with a history of hypersensitivity to temozolomide or other analogic alkylating agents. 12. Patient with severe myelosuppression 13. Patient with any other conditions under which investigators think the subject is not suitable for enrolment, such like having known that the subject may not have good compliance.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>prognosis</keyword>
	<keyword>supra-early chemotherapy</keyword>
</DOC>